高剂量他类药物在预防心脏导管术后对比诱导脏病的有效性
Montaser Elkholy1, Mohammad Akkawi2, George G Kidess3
1Department of Internal Medicine, Detroit Medical Center/Sinai Grace Hospital/Wayne State University, Detroit, USA.
Cureus
|May 7, 2025
概括
高剂量的他类药物显著降低了心脏导管治疗的患者的对比诱导性病 (CIN). 然而,这种保护作用在已经服用慢性他类药物治疗的患者中没有观察到.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对比诱导性病 (CIN) 是心脏导管术后的一种严重并发症.
- 高剂量的他类药物正在作为对CIN的潜在预防措施进行研究.
研究的目的:
- 评估术前高剂量他类药物在心脏导管患者中预防CIN的疗效.
- 为了评估前未服用他类药物和慢性治疗患者的益处.
主要方法:
- 随机对照试验 (RCT) 的最新系统审查和元分析,截至2024年6月.
- 包括的研究重点是高剂量他类药物给药周血管图.
- 排除了低剂量他类药物,非心脏手术或不清楚的CIN终点的试验.
主要成果:
- 对2312名参与者的聚合分析显示,高剂量他类药物可显著降低CIN (OR:0.47,P = 0.0007).
- 亚组分析显示,慢性他类药物治疗的患者没有显著的益处 (OR:1.03,P = 0.97).
结论:
- 术前高剂量他类药物在接受心脏导管治疗的未服用他类药物的患者中有效预防CIN.
- 高剂量的他类药物不会在已经接受慢性他类药物治疗的患者中提供对CIN的额外保护.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
392
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
392
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416


